Shaily Engineering Plastics Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 4 Aug 2026 | Consumer Durables | Market Cap: ₹14.6K Cr
FY '26 pen sales target: 30-35 million units, approximately 70% growth over previous year - Revenue growth in Healthcare segment: 53% YoY in FY '25, expected to contribute ~30% of total revenues in Shaily Engineering Plastics expects strong growth in revenues and margins year-on-year rather than quarter-on-quarter, with improving EBITDA margins aimed through executing current plans.
From Shaily Engineering Plastics Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹3,321
Market Cap
₹14.6K Cr
P/E Ratio
90.6
How does Shaily Engineering Plastics Ltd rank in Consumer Durables?
Compare Shaily Engineering Plastics Ltd against every Consumer Durables company this quarter on revenue, margins and earnings-call signals.
Shaily Engineering Plastics Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹224 Cr, net profit ₹49 Cr.
Full financials →📊 Revenue & Sales Performance
- →FY '26 pen sales target: 30-35 million units, approximately 70% growth over previous year
- →Revenue growth in Healthcare segment: 53% YoY in FY '25, expected to contribute ~30% of total revenues in next few years
- →Own IP-led insulin pens expected to grow at 20-30% CAGR over next 2 years
- →Anticipated 77% growth in pen sales driven by IP-led pen platform, especially non-insulin products
- →Capacity expansion: Adding 40-50 million pens capacity in next 18-24 months, reaching total of 80-90 million pens capacity
- →New product launches expected, including teriparatide in FY '26 with 2 customers planned
- →Other segments like Consumer and Industrial expected to grow steadily, with Consumer segment growing 17% YoY in FY '25
- →Potential medium to large capex in Consumer electronics in next 1-2 years based on customer agreements
📈 Profitability & Margins
- →Shaily Engineering Plastics expects strong growth in revenues and margins year-on-year rather than quarter-on-quarter, with improving EBITDA margins aimed through executing current plans.
- →FY '25 saw EBITDA margin expand by 350 bps to 22.7%, PAT margin increased by 290 bps to 11.8%, reflecting strong profitability growth.
- →Growth in healthcare segment (primarily pen injectors and auto-injectors) is a key driver, with 53% revenue growth in FY '25 and anticipated to comprise ~30% of revenues in coming years.
- →Pen sales are expected to grow 70-77% in FY '26, with total device volumes around 30-35 million units, further supporting revenue gains.
- →Expansion capex of ~INR150 crores planned to increase pen manufacturing capacity by 40-50 million units over 18-24 months, underpinning future volume growth.
- →Profitability is expected to improve with better asset turns (1.5x to 2x) and higher utilization rates over the next 2-3 years.
- →No specific EPS guidance provided, but sustained growth and margin expansion suggest positive future earnings trajectory.
🏗️ Capital Expenditure Plans
- →Current capex for FY '26 is approximately INR150 crores focused primarily on Pharma segment capacity expansion.
- →Planned addition of 40 million to 50 million pen manufacturing capacity over the next 18-24 months.
- →Post this expansion, total pen capacity expected to be in the range of 80 to 90 million pens.
- →Further capacity increase beyond 90 million pens will depend on firm customer commitments or purchase orders.
- →Total Pharma gross block after this capex expected to be around INR370 to INR375 crores.
- →No immediate land acquisition planned; expansion likely near existing facilities.
- →Additional medium to large capex possible in Consumer Electronics in the next 1-2 years if business plans with customers materialize.
- →Capex investments are made gradually and are aligned with committed volumes from customers to minimize risk.
💰 Fundraising & Capital Structure
- →There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
- →The company discusses capital expenditure plans, notably INR150 crores capex for pharma segment expansion (pen manufacturing capacity increase by 40-50 million pens).
- →Investments are described as being funded based on firm commitments from customers rather than through advances or external funding.
- →Debt-to-equity ratio as of March 31, 2025, stands at 0.4x, with long-term debt-to-equity at 0.07x, indicating moderate leverage but no mention of new debt raise.
- →Customer advances appear in current liabilities but are not linked to capex advances.
- →The management highlights disciplined capital use and focuses on organic capacity expansion aligned with firm orders.
- →No statements suggest immediate plans to raise equity or new debt as of May 2025.
📋 Order Book & Pipeline
- →Shaily Engineering Plastics is expanding pen manufacturing capacity by 40-50 million pens over 18-24 months, targeting a total capacity of 80-90 million pens.
- →Capex for this expansion is about INR150 crores, with additional investments expected for lab and support facilities.
- →Further capacity increases beyond 90 million pens will depend on firm customer commitments and purchase orders.
- →The company has signed 8 contracts with different customers for pen or auto injectors, primarily for GLP-1 and other therapies.
- →For Tirzepatide (Tirze) exhibit supplies, the company expects about 2 customers launching in FY '26.
- →Incremental pen/autoinjector sales of 12-15 million units targeted in FY '26 are spread across 3-4 customers with no single customer approval yet.
- →Discussions ongoing with customers for volume and capacity commitments for the next 3-5 years.
- →No explicit total order book value shared; capacity expansion is tied to customer firm orders.
Key Metrics
Frequently Asked Questions
What were Shaily Engineering Plastics Ltd Q4 FY25 results?
FY '26 pen sales target: 30-35 million units, approximately 70% growth over previous year - Revenue growth in Healthcare segment: 53% YoY in FY '25, expected to contribute ~30% of total revenues in Shaily Engineering Plastics expects strong growth in revenues and margins year-on-year rather than quarter-on-quarter, with improving EBITDA margins aimed through executing current plans.
What is Shaily Engineering Plastics Ltd share price analysis?
Shaily Engineering Plastics Ltd currently shows a neutral. The stock trades at a P/E of 90.6 with a market cap of ₹14,609 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shaily Engineering Plastics Ltd planning capital expenditure?
Current capex for FY '26 is approximately INR150 crores focused primarily on Pharma segment capacity expansion.
Keep Shaily Engineering Plastics Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.